BIOMARIN PHARMACEUTICAL INC BMRN

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Our San Rafael, California-based company, founded in 1997, has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, we seek to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.

In 2025, we achieved $3.2 billion in total revenues, including a significant contribution from our ongoing expansion of VOXZOGO, and we continued to grow our commercial business and advance our product candidate pipeline. We believe that the combination of our internal research programs, partnerships and acquisitions of external assets will allow us to continue to develop and commercialize innovative therapies for patients with serious and life-threatening rare diseases and medical conditions. We periodically conduct strategic portfolio assessments of research and development programs to determine which we believe have the strongest combination of scientific merit, opportunity for commercial success and potential value creation for stockholders. Based on such strategic portfolio assessments, certain programs that do not meet our threshold for further development and commercialization could be discontinued.

Last close 55.95 2026-10-23
Market cap $10.83B 2026-06-30 share count
52-week range 49.26 - 70.98

Valuation FY2025 figures against the last close

P/S3.4x
P/E31.1x
P/FCF14.9x
EV/EBITDA22.1x
Dividend yield—
Diluted EPS1.80

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $3.22B$2.85B$2.42B$2.10B$1.85B$1.86B$1.70B$1.49B$1.31B$1.12B
Cost of revenue $717.4M$580.2M$532.1M$503.0M$470.5M$524.3M$359.5M$315.3M$241.8M$209.6M
Gross profit $2.50B$2.27B$1.89B$1.59B$1.38B$1.34B$1.34B$1.18B$1.07B$907.2M
R&D $921.9M$747.2M$746.8M$649.6M$628.8M$628.1M$715.0M$696.3M$610.8M$661.9M
SG&A $1.15B$1.01B$892.4M$823.2M$759.4M$737.7M$680.9M$604.4M$554.3M$476.6M
Total operating expenses $2.81B$2.37B$2.23B$1.94B$1.93B$1.90B$1.80B$1.61B$1.33B$1.92B
Operating income $409.5M$484.2M$185.8M$161.0M-$82.3M-$43.4M-$100.5M-$123.5M-$14.7M-$803.4M
Interest expense $10.9M$12.7M$17.3M$16.0M$15.3M$29.3M$23.5M$43.7M$42.7M$39.5M
Pre-tax income $482.5M$541.8M$188.6M$149.6M-$75.3M-$49.0M-$94.8M-$142.7M-$35.9M-$831.0M
Income tax $133.6M$114.9M$20.9M$8.0M$11.3M$903.0M$71.0M$65.5M$81.2M$200.8M
Net income $348.9M$426.9M$167.6M$141.6M-$64.1M$854.0M-$23.8M-$77.2M-$117.0M-$630.2M
EPS, basic 1.822.250.890.76-0.354.72-0.13-0.44-0.67-3.80
EPS, diluted 1.802.210.870.75-0.354.50-0.13-0.44-0.67-3.81
Shares, diluted (wtd. avg.) 197.4M196.7M191.6M189.0M182.9M191.7M179.0M177.3M174.4M166.2M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $1.31B$942.8M$755.1M$724.5M$587.3M$649.2M$437.4M$494.0M$598.0M$408.3M
Short-term investments $248.9M$194.9M$318.7M$567.0M$426.6M$416.2M$316.4M$590.3M$797.9M$381.3M
Receivables $908.2M$660.5M$633.7M$461.3M$373.4M$448.4M$377.4M$342.6M$261.4M$215.3M
Inventory $1.30B$1.23B$1.11B$894.1M$776.7M$698.5M$680.3M$530.9M$475.8M$355.1M
Total current assets $3.95B$3.23B$2.96B$2.75B$2.27B$2.34B$1.94B$2.06B$2.21B$1.42B
Property, plant and equipment $952.5M$1.04B$1.07B$1.07B$1.04B$1.03B$1.01B$948.7M$896.7M$798.8M
Goodwill $196.2M$196.2M$196.2M$196.2M$196.2M$196.2M$197.0M$197.0M$197.0M$197.0M
Other intangibles $213.8M$255.3M$294.7M$338.6M$388.7M$417.3M$456.6M$491.8M$517.5M$553.8M
Total assets $7.59B$6.99B$6.84B$6.38B$6.00B$5.85B$4.69B$4.43B$4.63B$4.02B
Accounts payable $759.0M$607.0M$683.1M$573.0M$498.3M$492.5M$570.6M$437.3M$401.9M$370.5M
Total current liabilities $759.0M$607.0M$1.18B$588.9M$546.5M$492.5M$932.5M$523.2M$816.5M$439.3M
Total liabilities $1.51B$1.33B$1.89B$1.77B$1.74B$1.74B$1.57B$1.46B$1.82B$1.26B
Retained earnings $154.2M-$194.7M-$621.6M-$789.2M-$930.8M-$861.6M-$1.72B-$1.69B-$1.64B-$1.52B
Total equity $6.09B$5.66B$4.95B$4.60B$4.27B$4.10B$3.12B$2.97B$2.81B$2.77B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $828.0M$572.8M$159.3M$175.9M$304.5M$85.4M$48.3M$20.2M-$8.8M-$227.8M
Depreciation and amortisation $79.6M$96.4M$104.4M$102.0M$108.0M$105.2M$105.3M$95.7M$87.9M$96.9M
Stock-based compensation $181.4M$201.6M$207.1M$196.3M$197.3M$189.7M$159.9M$148.8M$140.3M$134.6M
Capital expenditure $103.0M$85.4M$96.7M$121.0M$95.6M$114.3M$145.0M$144.6M$199.2M$148.4M
Investing cash flow -$414.2M$136.5M-$111.2M-$20.0M-$366.3M-$53.6M-$31.0M$264.4M-$305.5M-$484.0M
Financing cash flow -$42.4M-$526.4M-$18.7M-$18.6M-$48.0K$181.1M-$74.7M-$388.0M$507.1M$727.1M
Buybacks ———$0$0$50.0M$0$0——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-026290.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -1B 0 1B 2B 3B 4B Revenue, FY2016: 1.1B Gross profit, FY2016: 907.2M Net income, FY2016: -630.2M Revenue, FY2017: 1.3B Gross profit, FY2017: 1.1B Net income, FY2017: -117M Revenue, FY2018: 1.5B Gross profit, FY2018: 1.2B Net income, FY2018: -77.2M Revenue, FY2019: 1.7B Gross profit, FY2019: 1.3B Net income, FY2019: -23.8M Revenue, FY2020: 1.9B Gross profit, FY2020: 1.3B Net income, FY2020: 854M Revenue, FY2021: 1.8B Gross profit, FY2021: 1.4B Net income, FY2021: -64.1M Revenue, FY2022: 2.1B Gross profit, FY2022: 1.6B Net income, FY2022: 141.6M Revenue, FY2023: 2.4B Gross profit, FY2023: 1.9B Net income, FY2023: 167.6M Revenue, FY2024: 2.9B Gross profit, FY2024: 2.3B Net income, FY2024: 426.9M Revenue, FY2025: 3.2B Gross profit, FY2025: 2.5B Net income, FY2025: 348.9M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $1.12B $1.31B $1.49B $1.70B $1.86B $1.85B $2.10B $2.42B $2.85B $3.22B
Gross profit $907.2M $1.07B $1.18B $1.34B $1.34B $1.38B $1.59B $1.89B $2.27B $2.50B
Net income -$630.2M -$117.0M -$77.2M -$23.8M $854.0M -$64.1M $141.6M $167.6M $426.9M $348.9M

Recent filings and events

  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed Item 1.01
  • Regulation FD disclosure Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event Item 8.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Material agreement signed Item 1.01
  • Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%